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Executive Summary 
 
 
Very high levels of patient adherence (greater than 95 percent) are required for antiretroviral therapy 
(ART) to be effective and to prevent the emergence of resistant viral strains (Paterson et al. 2000; 
Ickovics et al. 2002). Since 1997, antiretroviral (ARV) medications have been available in India through 
the private sector and some employer-supported health insurance programs. It is estimated that India has 
5.1 million HIV-infected persons (NACO 2004), some of whom have been on ART for several years. 
However, very little information is available on the levels of adherence to ART among people living with 
HIV/AIDS in India. 
 
With increased availability of ART, HIV-positive individuals are living healthier lives and continuing or 
resuming sexual activity. But, optimism related to ARTs success in slowing disease progression, 
reducing viral load, and improving health status may lead to more risky sexual practices and a possible 
increase in transmission of infections. Determining the sexual behavior of HIV-positive persons on ART 
is therefore an area of special interest and concern.  
 
To meet these knowledge gaps, the Horizons Program, in collaboration with research partners in Delhi 
and Pune, conducted a study to assess current levels of adherence to ART among a sample of people 
living with HIV/AIDS, identify the factors that influence their adherence to treatment, and determine their 
sexual risk behaviors. The study also examined the economic burden of ART on the household. Findings 
from the study provide important insights that are immediately relevant to the scale-up of the national 
ART program, which was launched in April 2004. 
 
 
Methods 
 
Three hundred and ten HIV-positive patients currently on ART and attending one private and three public 
sector health facilities in Pune and Delhi were interviewed between May and August 2004. The sample of 
clients from the private clinic was mostly paying out-of-pocket for their treatment (n = 252/263). The 
remaining private clinic clients (n = 11) and those using the public sector facilities (n = 47) were 
receiving free ARVs through employer-provided, government-supported health insurance programs. A 
semi-structured questionnaire adapted from adherence instruments developed by the Adult AIDS Clinical 
Trials Group (AACTG) was used for data collection.  
 
Adherence was measured using a 4-day patient self-report. Mean 4-day adherence was calculated by 
dividing the number of pills actually taken by the number of pills prescribed for 4 days x 100.  
Higher adherence was defined as a mean 4-day adherence of ≥ 90 percent and lower adherence as a mean 
4-day adherence of < 90 percent. Other measures of adherence included (a) the number of missed doses 
over the last week, (b) the last time a full day of medication was missed, (c) the number of times 
treatment was stopped for more than one week, and (d) the frequency of following the medication dosage 
schedule.  
 
The key themes of analysis for sexual risk behavior were type of partners, knowledge of partners status, 
disclosure of ones own HIV status to partners, condom use at last sex, and consistent condom use. 
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Characteristics of the Sample 
 
The mean age of respondents was 37 years (range 2370 years). The majority of patients were employed 
(82 percent) and currently married (85 percent). Most were male (84 percent), although the percentage of 
women was higher in the group receiving free ARVs than in the group paying for the medication out-of-
pocket (28 percent versus 13 percent). One reason for this difference is that employer-provided, 
government-supported insurance programs extend coverage to the families of employees.  
 
Ninety-eight percent of respondents were on a non-protease-inhibitor-based treatment regimen. Eighty-
eight percent of respondents (n = 272) were on a first-line Nevirapine-based regimen; seven percent on an 
Efavirenz-based regimen (n = 22), and three percent (n = 9) on other combinations that include 
didanosine (DDI) and abacavir (ABC). Two percent (n = 7) were taking protease-inhibitor-based 
treatment regimens containing NRTI (nucleoside reverse transcriptase inhibitor) combinations with 
Ritonavir-boosted Indinavir or Nelfinavir.  
 
 
Key Findings 
 
The mean 4-day adherence was high in this population; however, adherence decreased over 
longer recall periods.  
 
The self-reported mean 4-day adherence for the sample was 94.5 percent. Sixteen percent of respondents 
reported missing one or more doses over the last four days; more than a quarter of the respondents 
reported not having followed the medication schedule over the past four days. Twenty percent of 
respondents reported missed doses over the past seven days; a similar percentage reported missing a full 
days medication within the last three months. Sixteen percent of respondents reported having stopped 
medications for more than a week at least once since initiating ART. There were no differences between 
males and females on these measures. 
 
Commonly cited reasons for missing doses over the past week included being busy with other things and 
forgetting (38 percent), being away from home (34 percent), and running out of pills (26 percent). Half of 
those who ran out of pills reported stock-outs in public sector dispensaries. Not having money to purchase 
medications (5 percent), not understanding instructions (4 percent), and feeling ill (4 percent) were 
mentioned less frequently.  
 
 
Severe depression and obtaining free ARVs through insurance programs were the main 
predictors of lower adherence.  
 
Through multivariate analysis, severe depression and obtaining free ARVs were found to be significantly 
associated with lower adherence (defined as a mean 4-day adherence rate of < 90 percent). Patients with 
severe depression were four times more likely to report lower adherence compared to those with minimal 
depression (95 percent CI 1.63912.269, p = .002) and patients receiving free ARVs were four times 
more likely to report lower adherence compared to patients paying out-of-pocket for their treatment (95 
percent CI 1.42211.542, p = .009).  
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Lower adherence was documented among patients receiving free ARVs, even after 
controlling for economic status.  
 
Mean 4-day adherence was significantly lower among patients receiving free ARVs through insurance 
programs compared to patients paying out-of-pocket (81 percent versus 96 percent, p < 0.001).  
 
Adherence in the group receiving free ARVs was lower for all other measures of adherence: missed doses 
over four days, missed doses over the last week, last time a full day of medication was missed, number of 
times treatment was stopped for more than one week, and frequency of following medication dosage 
schedule.  
 
Adherence was lower among patients receiving free ARVs through insurance programs compared to 
patients paying out-of-pocket across the first three economic quartiles, even after controlling for 
economic status. 
 
 
For clients with no insurance coverage, being on ART is a heavy economic burden and 
most would switch to a free program, if available.  
 
The study found that for clients without any insurance coverage, being on ART is a heavy economic 
burden, which highlights the need for financing mechanisms that include paying for drugs and tests. At 
the same time, the results also suggest that zero out-of-pocket expenditure on treatment may be a 
deterrent to adherence, which means that more consideration should be given to the pricing of the 
treatment program in order to maximize adherence.  
  
Seventy-one percent of clients who did not have any coverage and were paying out-of-pocket for their 
treatment said they would move to the free ARV program funded by the government if they could, mostly 
for financial reasons. Concerns about confidentiality and the quality of care and of medications in public 
sector facilities were the main reasons why 19 percent indicated that they would not switch to a 
government facility.  
 
 
Most respondents reported being sexually active in the past six months, primarily with a 
regular partner.  
 
Sixty-one percent of respondents reported having had sexual intercourse in the past six months. More 
respondents with minimal to mild depression, who started treatment at higher CD4 counts  
(> 200 cells/ mm3), and who were married reported sexual activity in the past six months. No difference 
between men and women was noted in reported sexual activity. Time since diagnosis of HIV infection 
and time on ART were not associated with reporting sex.  
 
The majority of respondents reported sex with a regular partner (96 percent); proportions were similar for 
men and women. All respondents who reported sex with a casual partner (4 percent) or a sex worker (2 
percent) were men. No men reported sex with a male partner during the reference period. 
 
  
 4 
More respondents reported knowing the HIV status of their regular partner than reported 
disclosing their own status to them.  
 
Eighty-three percent of respondents who had sex with a regular partner reported knowing their partners 
HIV status. More women reported having an HIV-positive regular partner while more men reported 
having an HIV-negative partner or one of unknown status. A smaller proportion (74 percent) of 
respondents reported having disclosed their HIV status to their regular partner. Proportions were similar 
for men and women. 
 
None of the respondents who reported sex with a casual partner or sex worker knew that partners HIV 
status or disclosed their own serostatus to them.  
 
 
Respondents with an HIV-positive partner and with minimal to mild depression were more 
likely to disclose their HIV status to a regular partner.  
 
The highest level of disclosure to a regular partner was observed among respondents with an HIV-
positive partner (83 percent); lower disclosure rates were found among respondents with an HIV-negative 
partner (74 percent) and among those with a partner of unknown HIV status (52 percent; p < 0.003). A 
significantly greater proportion of respondents with minimal to mild depression (94 percent) disclosed 
their HIV status to their regular partner than respondents with moderate to severe depression (78 percent; 
p = 0.002). 
 
 
Reported condom use was high with regular partners.  
 
Eighty-nine percent of respondents who reported sex with a regular partner reported using a condom at 
last sex. There was no significant difference between men and women. All respondents who reported sex 
with a casual partner or sex worker reported using a condom at last sex with that type of partner.  
 
Condom use at last sexual contact with a regular partner was associated with education, partners HIV 
status, and depression. Respondents with less than five years of education (65 percent) reported 
significantly lower condom use when compared to those with 612 years of education (92 percent) and 
those with a university level of education (93 percent; p = 0.001). Respondents with moderate to severe 
depression (78 percent) were less likely to report condom use at last sexual contact than respondents with 
minimal to mild depression (94 percent; p = 0.002). Respondents with an HIV-negative partner (96 
percent) were more likely to report condom use at last sexual contact with a regular partner than 
respondents with a HIV-positive partner (83 percent) and with a partner of unknown status (87 percent; p 
= 0.002). Consistent condom use (always used a condom) with a regular partner was reported by 80 
percent of respondents. 
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Program Implications 
 
This exploratory study was conducted among HIV-infected individuals accessing ARVs in two categories 
of health service facilities: the private sector and the insurance-based public sector. Although the self-
reported mean 4-day adherence was high among study participants, the data indicate that adherence was 
lower among patients who received free ART through insurance-based programs. No information is yet 
available on adherence levels among patients who are receiving free ARVs through the national ART 
program to which the data from this study can be compared. Therefore, there is a need for a larger multi-
site study that compares HIV-infected persons receiving free ART through the national ART program to 
HIV-positive clients of a range of private providers and private facilities to better understand the links 
between treatment adherence, financing of ART, and quality of care.  
 
Findings of lower adherence among patients receiving free ARVs through insurance-based public sector 
facilities may be an early indicator of adherence levels among clients of the national ART program. These 
findings underscore the need for a strong monitoring and evaluation component in the national program 
as it scales up and a strong focus on (a) adequate preparation of patients prior to initiating ART, (b) 
regular assessment of adherence levels during follow-up, and (c) provision of ongoing adherence support 
for patients.  
 
The national ART program needs to prepare for an influx of patients currently accessing care services in 
the private sector. Most respondents paying out-of-pocket for ART in this study would switch to a free 
program if they could. However, they have a number of concerns about the quality of care at government 
facilities (e.g., quality of ARV medications, confidentiality, continuous supply of medications) that 
should be considered by program administrators as the national ART program is rolled out.  
 
The study found that while out-of-pocket expenses for treatment pose a significant economic burden on 
clients who pay for services, these expenses could also influence adherence positively. Policymakers may 
want to consider a pilot project to assess optimal levels of user fees to maximize adherence yet minimize 
the economic burden of ART on households..  
 
Given that severe depression was a key predictor of lower adherence, health providers should check for 
this condition during adherence risk assessment of patients before ART is initiated. Consideration during 
adherence counseling should also be given to other factors that were found to influence adherence in this 
study, such as lower education levels, starting ART at higher CD4 cell counts, being unemployed, having 
moderate to severe side effects as a result of taking ART, and taking four or more medications.  
 
The evidence from this study highlights the need to expand the scope of prevention programs to include 
HIV-positive populations, with a special focus on facilitating disclosure of HIV status and consistent 
condom use with regular partners. Interventions that integrate HIV prevention activities with HIV/AIDS 
care services are required.  
 
This study included relatively few women. Although the respondents were not representative of the entire 
population accessing ART services in India, the low figure still calls attention to the need for 
policymakers to make sure that women are included in the national ART program. 
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Introduction 
 
 
Antiretroviral therapy (ART) has been successful in dramatically decreasing the morbidity and mortality 
caused by HIV. This success, coupled with lower-priced drugs, the availability of generic drugs, and an 
increase in donor funding, has led numerous governments of developing nations to implement treatment 
programs for their HIV-positive citizens.  
 
The HIV prevalence rate in India is estimated to be less than one percent; however, this translates to over 
five million HIV-infected individuals, exceeded only by South Africa in terms of the total number of 
people estimated to be infected by the virus (UNAIDS 2004). In April 2004 the Indian government 
announced a plan to provide ART in high-prevalence states through public sector health facilities. The 
program underwent a rapid scale-up and ART is currently being provided in 25 sites around the country. 
Prior to April 2004, ART was only available in private-sector clinics and in a few public-sector health 
facilities linked to government agencies or employers that provided workplace health insurance coverage.  
 
A major concern in scaling up ART in resource-limited settings is the potential emergence of drug-
resistant viral strains. To prevent the emergence of such strains, optimal patient adherence to ART is 
necessary. Levels of adherence in excess of 95 percent are required to ensure treatment success, adequate 
viral load suppression, improved immune status, and the slowing of disease progression (Paterson et al. 
2000; Ickovics et al. 2002). To date there has been very little scientific data on treatment adherence in 
India. 
 
It is estimated that 85 percent of new HIV infections in India are the result of sexual transmission (NACO 
2004). HIV is spreading beyond high-risk groups to the general population. Women are increasingly 
affected, comprising one out of four new HIV-positive cases. With increased availability of ART, HIV-
positive individuals are living healthier lives and continuing or resuming sexual activity, thus increasing 
the risk of HIV transmission. There is some evidence from western countries that among populations of 
men who have sex with men who are on ART, levels of unprotected sex and the incidence of sexually 
transmitted infections (including HIV) have increased (Chen et al. 2002; Katz et al.2002; Van der Ven et 
al.2002; Stolte et al.2001; Morbidity Mortality Weekly Report 1999). Optimism related to the success of 
ART in slowing disease progression, reducing viral load, and improving health status may lead to more 
risky sexual practices and a possible increase in transmission of infections. Preventive and risky sexual 
behavior of HIV-positive persons on ART has therefore become an area of special interest and concern.  
 
Findings from exploratory research at sites in Pune and Delhi, India, provide information on these two 
important issues: adherence to ART and sexual risk behavior among clients on ART.  
 
Examining adherence and sexual behavior among patients on ART 
7 
Methods 
 
 
Objectives 
 
A team of researchers and service providers conducted a diagnostic study among people living with 
HIV/AIDS receiving ART at selected private and public sector health facilities in Delhi and Pune. The 
objectives of the study were to: 
• Assess the current levels of adherence to ART among clients. 
• Identify the factors that influence adherence to treatment.  
• Examine the sexual risk behaviors of clients. 
• Determine the economic burden of ART on clients.  
 
 
Study Design 
 
The study employed a cross-sectional design. HIV-infected persons receiving ART at selected facilities 
were interviewed between May and August 2004 as they came in for routine follow-up visits at outpatient 
clinics (patients admitted in wards were not interviewed). 
A semi-structured survey questionnaire adapted from 
adherence instruments developed by the Adult AIDS 
Clinical Trials Group (AACTG) was used.  
 
Interviews were conducted in Hindi, Marathi, or English, 
as requested by patients. Trained research interviewers 
from outside the health facilities conducted the interviews. 
Ethical approval was obtained from the ethical review 
board of the Population Council and the management of 
each participating health facility. Written informed consent 
was obtained from all participants.  
 
 
Study Sites  
 
A convenience sample of four health facilities was selected. In Pune, both a private and a public sector 
health facility were chosen and in Delhi two public sector facilities were chosen. At the time this study 
was initiated the national ART program had yet to be implemented. ARVs were only available through 
private sector clinics, which were treating the majority of HIV-infected persons, and through employer-
based health insurance programs, including those administered by public sector health facilities. 
 
The sites participating in the study were: 
• Ruby Hall Clinic and Grant Medical Foundation, Pune 
• Employees State Insurance Corporation Hospital, Chinchowad, Pune 
• Employees State Insurance Corporation Hospital, Jhilmil, New Delhi 
• Northern Railway Hospital, New Delhi 
Research Partners 
 
1. Ruby Hall Clinic and Grant Medical 
Foundation 
2. Employees State Insurance 
Corporation 
3. Northern Railway Hospital 
4. Institute of Economic Growth, 
Delhi University 
5. Horizons, Population Council 
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Ruby Hall Clinic (RHC) is a private sector health facility providing health care services on a fee-for-
service basis. RHC also provides care services to clients from employer-based health insurance programs, 
such as the Central Government Health Scheme (CGHS) as well as private insurance schemes. Through 
its charitable arm, the Grant Medical Foundation, RHC provides free health care to a limited number of 
poor patients.  
 
The Employees State Insurance Corporation (ESIC) is an employer-based, social security organization 
with a network of health facilities nationwide, including hospitals in Chinchowad and Jhilmil. ESIC falls 
under the purview of the Indian Ministry of Labor. ESIC provides health care to employees of 
organizations employing at least 25 people who earn less than Rs. 6000 (US$140) per month. 
Organizations covered include small-scale industrial units, export houses, factories, restaurants, security 
services, and shopping stores. Coverage extends to the families of employees as well as to the workers 
themselves. 
 
The Indian Railways provides health care to employees and their families through a network of 
dispensaries and hospitals across the country. This is an employer-based insurance program. Employee 
cadres include engineers, medical officers, administrative staff, drivers, maintenance crew, lines men, and 
cleaners. The Northern Railway Hospital (NRH) is the regional referral hospital for railway workers and 
their families in Delhi and surrounding states in the Northern region.  
 
HIV-positive adult patients who had been on ART for at least 30 days were interviewed. Since small 
numbers of HIV-infected persons were receiving ART through public sector facilities, all patients 
receiving ART at ESIC and NRH were invited to participate in the study. At Ruby Hall Clinic, which 
provided ART to approximately 800 patients at the time of the study, the first 273 clients (34 percent) 
who came in for follow-up visits were interviewed. The sample size was based on population proportion 
of 50 percent (P) and confidence level of 90 percent, with absolute precision of 5 percent points (sample 
size = z21-α/2P(1-P)/d2) to have sufficient variation in the population characteristics (e.g., sex, education, 
economic status) that may influence adherence.  
 
Although formal adherence counseling was not provided at any of the sites, physicians at both the private 
and public sector facilities provided treatment- and adherence-related advice to patients. In the private 
sector, physicians also discussed the financial implications of long-term ART and assessed patient 
readiness and ability to continue treatment prior to initiating ART. The provision of support to the patient 
by the family was encouraged whenever possible at all sites.  
 
 
Study Population and Recruitment 
 
The total number of HIV-positive participants who completed interviews in the Delhi and Pune sites was 
310. At RHC in Pune 263 participants were interviewed; an additional 10 individuals were asked to 
participate, but seven withdrew consent and three did not complete the interview because of time 
constraints; 252 individuals interviewed at RHC paid out-of-pocket for their treatment and 11 had 
insurance coverage through the CGHS.  
 
As a very small number of clients was receiving ART in the three public sector facilities, all were invited 
to participate in the study; 47 patients out of a total of 57 on ART (82 percent) completed the interview, 
six did not visit the clinic for a follow-up visit during the recruitment period, and four refused to be 
Examining adherence and sexual behavior among patients on ART 
9 
interviewed. ARVs, routine medical care, and routine monitoring were provided free of cost at NRH and 
the two ESIC facilities. 
 
 
Measures 
 
Adherence was measured using self-reported data. Five measures of adherence were used that reflected 
different periods of recall:  
• Adherence over the past four days. 
• Adherence over the past one week. 
• The last time a full days medication was missed. 
• The number of times treatment was stopped for more than one week since initiating ART. 
• How closely the respondent followed the medication-dosing schedule over the last four days.  
 
The mean 4-day adherence was calculated by dividing the number of pills actually taken by the number of 
pills prescribed for the four days multiplied by 100. Higher adherence was defined as a mean 4-day 
adherence rate of ≥ 90 percent and lower adherence as a mean 4-day adherence rate of < 90 percent. 
Lower adherence for the 4-day period (< 90 percent) was the primary outcome measure used in 
multivariate analysis to determine the independent predictors of adherence. The researchers used a less 
stringent cut off of < 90 percent because of emerging evidence suggesting that viral load suppression may 
be achievable at lower adherence levels with non-nucleoside reverse transcriptase inhibitors (NNRTI) 
treatment regimens (Maggiolo et al.2005; Weiser et al.2004), which is what the majority of the sample 
was taking. This level of adherence may also be more realistic for patients to achieve.  
 
 
Data Analysis 
 
Chi Square and Kruskall Wallis (non-parametric test) tests were used to assess significance for categorical 
variables. T-tests and Mann Whitney (non-parametric test) tests were used to assess significance between 
the groups (e.g., paying for ARVs  versus not paying for ARVs) for continuous variables. Independent 
predictors of lower adherence were determined using logistic regression analysis. A p value of < .05 was 
considered significant.  
 
Researchers explored the factors influencing adherence in this population. Analysis was done at two 
levels: bivariate analysis using Chi Square tests was done at the first stage to explore associations and to 
assess significance between individual variables of interest and adherence. This was followed by 
multivariate analysis using binary logistic regression with significantly related variables to determine the 
predictors of lower adherence.  
 
 
Limitations of the Study 
 
All quantitative data in this report are based on interviews with clients from a convenience sample of 
health facilities. Although convenience samples cannot be used to generalize to larger populations, the 
findings reveal important insights into adherence and sexual risk behavior among HIV-infected 
populations receiving treatment through both private and government health services.  
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At the time the study was undertaken, the national ARV program had not been initiated and very few 
patients were receiving ARVs in the public sector. Our sample includes a small number of people 
receiving free ARVs from the public sector through employer-supported, insurance-based programs 
(ESIC and NRH). Clients currently accessing ART through the national ART program may come from 
different socioeconomic backgrounds; nevertheless, the findings provide useful data that are relevant to 
the scale-up of the national program.  
 
The study did not examine adherence among HIV-infected individuals who may have discontinued 
treatment or dropped out of the program.  
 
The study used self-reported data to assess adherence. Self-reported adherence has been shown to 
correlate well with viral load levels (Liu et al. 2001; Duong et al. 2001; Nieuwkerk et al. 2005). However, 
self-reported data may overestimate adherence; therefore, it is useful to keep in mind that adherence rates 
may actually be lower than those reported, particularly when higher levels of adherence are reported by 
patients. When patients report lower levels of adherence, self-reported data is a more accurate measure 
(Nieuwkerk et al. 2005). 
 
Because the study was cross-sectional, other measures of adherence, such as pill counts and MEMS (i.e., 
an electronic chip inserted in the lid of the medication bottle that monitors the opening and closing of the 
lid) were not feasible because patients were not followed over time.  
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Results 
 
 
Characteristics of the Sample 
 
Table 1 presents the characteristics of the sample disaggregated by the type of payment for ART: out-of-
pocket (n = 252) or free through an insurance program (n = 58). The majority of patients in the sample 
were male, employed, and currently married. More than a third had a university education, although a 
greater proportion of respondents paying out-of-pocket for ART had this level of education compared to 
those receiving free ART through an insurance program. The mean age of respondents was 37 years 
(range: 2370 years). More women were receiving ART at public-sector facilities than at private health 
facilities. One reason for this is that the employer-based insurance programs operating out of the public-
sector facilities extend treatment coverage to families of employees, including spouses. The sample 
included six couples interviewed at NRH and ESIC, Delhi.  
 
Economic status (ES) was based on ownership of assets. Clients accessing care in the private sector were 
almost equally distributed across ES quartiles. The quartiles were based on asset scores; quartile one 
included respondents with the lowest scores and quartile four those with the highest scores. Among 
clients receiving free ART through insurance programs, the majority were distributed across the first three 
ES quartiles; very few fell into the highest ES quartile. 
 
Ninety-eight percent of respondents were on a non-protease inhibitor-based treatment regimen. Of these, 
88 percent of respondents were on a first-line Nevirapine (NVP)-based regimen (160 on stavudine 
(D4T)/Lamivudine (3TC)/ NVP and 112 on zidovudine (ZDV) / 3TC / NVP); 7 percent on a first-line 
Efavirenz (EFV)-based regimen (10 on D4T/3TC/EFV and 12 on AZT/3TC/EFV); and 3 percent on other 
combinations of didanosine (DDI) and abacavir (ABC). Two percent were taking protease inhibitor-based 
treatment regimens containing NRTI (nucleoside reverse transcriptase inhibitor) combinations with 
Ritonavir-boosted Indinavir or Nelfinavir.  
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Table 1  Background information of study participants (n = 310) 
 Paid out-of-pocket for ART 
n = 252 (%) 
Received free ART 
n = 58 (%) 
Total 
n = 310 (%) 
Sex*    
    Male 219 (87) 42 (72) 261 (84) 
    Female   33 (13) 16 (28)   49 (16) 
Age group    
    Less than 30 years   38 (15) 13 (22)   51 (16) 
    31 to 45 years 173 (69) 31 (53) 204 (66) 
    More than 45 years   41 (16) 14 (24)   55 (18) 
Education*    
    Less than 5 years of school   9 (4) 21 (36)   30 (10) 
    6 to 12 years of school 135 (54) 30 (52) 165 (53) 
    University 108 (43)   7 (12) 115 (37) 
Employment    
    Employed 212 (84) 43 (74) 255 (82) 
    Unemployed   40 (16) 15 (26)   55 (18) 
Marital status    
    Currently married 210 (83) 53 (91) 263 (85) 
    Single (never married) 20 (8) 1 (2)  21 (7) 
    Separated/widowed 22 (9) 4 (7)  26 (8) 
Economic status*    
    Quartile 1   62 (25) 26 (45)   88 (28) 
    Quartile 2   54 (21) 16 (28)   70 (23) 
    Quartile 3   69 (27) 12 (21)   81 (26) 
    Quartile 4   67 (27) 4 (7)   77 (23) 
Time since HIV diagnosis    
    Less than 12 months   42 (17) 13 (22)   55 (18) 
    13 to 24 months   60 (24) 13 (22) 73 (24) 
    More than 24 months 150 (59) 32 (55) 182 (59) 
Time since starting ART    
    Less than 12 months 106 (42) 22 (38) 128 (41) 
    13 to 24 months   70 (29) 15 (26)   85 (27) 
    More than 24 months   76 (30) 21 (36)   97 (31) 
CD4 at start of ART*    
    Less than 100 cells 124 (49)  9 (17) 133 (44) 
    101 to 200 cells   98 (40) 16 (30) 114 (37) 
    More than 200 cells   30 (12) 29 (54)   59 (20) 
Current depression*    
    Minimal 131 (52) 16 (28) 147 (48) 
    Mild   36 (14) 11 (19)   47 (15) 
    Moderate   45 (18)   9 (15)   54 (17) 
    Severe   39 (16) 22 (38)   61 (20) 
 
Chi square significance < .01 
Note: Percentages may not add up to 100 because they were rounded up to the nearest whole. 
Examining adherence and sexual behavior among patients on ART 
13 
A majority (59 percent) of study participants were diagnosed with HIV more than 24 months ago and 41 
percent had initiated ART in the past 12 months.  
 
National guidelines recommend that ART be initiated when the patients CD4 count is ≤ 200 cells/mm3 or 
when the patient has been clinically diagnosed with Stage IV disease (WHO classification for disease 
staging). Treating physicians provided baseline CD4 counts from patient medical records. There was a 
significant difference in CD4 cell counts and the initiation of ART between those patients who paid out-
of-pocket and those who received ART for free from their insurance program. Almost half of the paying 
group initiated ART at an advanced stage of HIV disease (CD4 cell counts ≤ 100 cells/mm3). In contrast, 
more than half the patients receiving free ARVs through insurance programs began ART at CD4 cell 
counts > 200 cells/mm3. 
 
Knowledge of the patients HIV disease and its management was explored. Respondents were asked what 
they understood about CD4 cell counts for initiating and monitoring treatment; open-ended answers were 
collected and analyzed qualitatively. Ninety-three percent of respondents noted that a CD4 count test had 
been done. However, 61 percent of these respondents did not know what the CD4 count measures and 54 
percent did not know how it is expected to change with treatment. (Data not shown in table.)  
 
Current depression scores were assessed using the Beck Depression Inventory II (BDI II) © 1996 Aaron 
T Beck. BDI II is a long-standing, validated, and widely used tool to assess current depression over the 
past week. Overall, almost half the respondents reported minimal depression scores. Nearly a fifth of the 
patients were severely depressed. Respondents receiving free ART were more likely to report higher 
depression scores compared to those paying out-of-pocket. 
 
 
Adherence 
 
Measures of adherence 
 
As Table 2 indicates, the mean self-reported four-day adherence for all patients was 93.5 percent. Sixteen 
percent of respondents reported having missed one or more doses in the last four days.  
 
Over longer periods of recall, reported adherence was lower. Twenty percent of respondents reported 
missing doses in the past seven days. When respondents were asked about the last time that they missed a 
full days dose of medication, 33 percent reported that they had ever missed a full day of medication. 
Sixteen percent of respondents reported that they had stopped taking their medication for longer than a 
week at least once since initiating ART. More than a quarter of the respondents reported not having 
followed the medication schedule over the past four days. There were no significant differences in 
reported adherence between men and women on any measure of adherence. 
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Table 2  Self-reported adherence by sex 
 Percent 
 Males 
(n = 261) 
Females 
(n = 49) 
Overall 
(n = 310) 
Mean self-reported 4-day adherence    93.5    93.4    93.5 
Missed one or more doses in 4 days 15 18 16 
Missed doses over last week (7 days)    
    No doses missed 80 78 80 
    1 to 2 doses missed 12 16 13 
    3 or more doses missed   8   6   7 
Last time missed a full day’s medication    
    Never 66 67 67 
    In the last 4 weeks 13 10 13 
    Between 1 to 3 months   8 12   9 
    More than 3 months back 12 10 11 
Number of times treatment stopped for more than  
1 week 
   
    Never 83 86 84 
    Once 11   8 10 
    2 or more times   6   6   6 
How closely did the client follow the ARV 
medication schedule over the past 4 days 
   
    Always 73 71 73 
    Some or most of the time 21   8 19 
    Never   6 20   8 
    
Note: Percentages may not add up to 100 because they were rounded to the nearest whole.  
 
 
Reasons for missing medications 
 
Adhering to the dosage schedule: For optimum bioavailability and maximum effect, antiretroviral 
medications must be taken at regular intervals throughout the day. For example, Triommune (D4T, 3TC, 
NVP) should be taken every 12 hours. Study participants were asked how well they were able to follow 
the dosage schedule over the past four days. Seventy-three percent of respondents reported having no 
problems following the dosage schedule as prescribed by their physician. Nineteen percent of respondents 
reported following the schedule some of the time and eight percent of respondents reported never 
following the dosage schedule.  
 
(I often) get delayed by 1–2 hours, but (I have) never taken a double dose, because the doctor said 
it causes problem.  
55-year-old female  
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I could not take in the morning so took in the afternoon, but never left [forgot to take medicines]. 
 26-year-old-female  
 
Missed doses over the past week: Twenty percent of respondents (n = 62) reported missing doses during 
the past week. These respondents were asked in open-ended questions to cite reasons for the missed 
doses; multiple reasons were permitted. The most commonly cited reasons for missing doses over the past 
week were forgetting to take the medicine (38 percent), being away from home (34 percent), and running 
out of pills (26 percent). For 9 of the 19 respondents who reported running out of pills, the reason was 
public sector dispensary stockouts. Other reasons for missing doses included financial restrictions (5 
percent), lack of understanding of dosing instructions (4 percent), feeling ill (4 percent), high pill burden 
(2 percent), side effects (2 percent), and depression (2 percent). 
 
I don’t miss my medicines, but I need to remind my wife to take her medications as she gets busy 
with housework and forgets.  
51-year-old male 
 
If medicines are not there [in the dispensary] they tell us to come back. Once or twice they  have 
done so for a week.  
32-year-old female accessing services in the public sector 
 
On Mondays, I leave [don’t take medicines] because of fasting.  
36-year-old female 
 
Missing medications for more than one week: The 51 respondents who reported missing medications for a 
period of more than a week were asked in open-ended questions to provide reasons for doing so. The 
most frequently cited reasons were financial difficulties (25 percent) and travel away from home (20 
percent). Eighty-five percent of patients who reported financial difficulties were paying out-of-pocket for 
ARVs.  
 
 
Reasons for regularly taking medications 
 
Patients who reported never missing medications were asked to elaborate in open-ended questions on 
their reasons for regularly taking their medication. The most commonly cited reason was a desire to be 
healthy and avoid illness. In addition, a doctors advice and emphasis on taking medications regularly 
(mostly mentioned by private sector patients) were important factors. Many respondents indicated that 
they had a desire to live for their families and that family support was very important for taking 
medications regularly. The cost of treatment and the money invested in the respondents health was 
another important reason for adhering to medications. Respondents also viewed adherence as a means of 
preventing frequent illnesses and some viewed adherence as a cost-saving mechanism.  
 
I have not missed any pill from the day I started taking medicines. You can see that all those 
patients who were having illness are no more and here I am working hard and sitting healthy in 
front of you.  
46-year-old male 
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I want to be alive for my wife and children. I should be hopeful as research is going on, something 
will come up.  
37-year-old male 
 
As the doctor told me that if you are going to take it regularly then only it will work. Before I used 
to get some or the other health problem like fever and treating that was (more) expensive 
compared to this.  
39-year-old male  
 
 
Reported side effects 
 
Many ARVs have associated side effects that can be either temporary in nature (three to four weeks) or 
more permanent, which often require a change of medication. Study participants were asked to report on 
symptoms related to side effects experienced in the past 30 days and to grade them according to their 
severity on a scale of 0 to 3 (0: none reported; 1: present but not bothersome; 2: present and mildly to 
moderately bothersome; 3: present and severely bothersome). Twenty commonly experienced side effects 
adapted from a validated and widely used AACTG questionnaire were listed (NIAID AACTG Symptoms 
Distress Module).  
 
As Table 3 illustrates, the most frequently reported symptoms were numbness or tingling in the hands and 
feet (42 percent), changes in body and face appearance (lipoatrophy/lipodystrophy; 38 percent), fatigue or 
loss of energy (38 percent), skin rashes (36 percent), muscle aches and joint pains (35 percent), and 
feelings of depression (35 percent). Of those who reported symptoms, less than 12 percent reported them 
to be severe. Fatigue or loss of energy was most often reported as severely bothersome.  
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Table 3  Self-reported symptoms related to side effects (n = 310) 
Side effects % reported  
by patients 
% reporting 
them as severely 
bothersome* 
Neurological/mood   
    Dizziness/lightheadedness 22 12 
    Pain/numbness/tingling in limbs 42 13 
    Memory loss 21 11 
    Feeling sad, down, depressed 35   5 
    Anxiety/nervousness 22 12 
    Sleep disturbances 26   8 
Gastrointestinal   
    Nausea/vomiting 21 11 
    Diarrhea 20   8 
    Loss of appetite/taste 25 11 
    Bloating/pain in abdomen 27   3 
Connective tissue and skin   
    Skin rash, dryness, or itching 36   5 
    Hair loss or change in way hair looks 16 12 
    Muscle aches and joint pains 35 12 
Respiratory   
    Cough or breathlessness 24   4 
Bodily changes   
    Changes in body/face looks - fat loss or gain 38   2 
    Problems with wasting or weight loss 29   6 
General   
    Headache 27 12 
    Sexual problems: loss of desire or satisfaction 25   6 
    Fatigue or loss of energy 38 19 
    Fever chills or night sweats 23 13 
 
*Of those who reported the side effect 
Note: Percentages may not add up to 100 because they were rounded to the nearest whole 
 
 
As noted above, each side effect was scored on a four-point scale (0 to 3) and a total score was calculated 
for each patient. The mean score for all patients was 8.27 (range 0 to 60). Overall, 9 percent of patients 
reported no side effects (a score of 0), 80 percent had low scores (120), 9 percent had moderate scores 
(2140), and only 2 percent had high scores (4160). As Figure 1 illustrates, there were no significant 
differences in scores between patients on ART for different periods of time (p = .330).  
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Figure 1  Side effect scores reported by patients on ART 
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Because side effects are expected in the first few months after initiating ART, we explored differences in 
reported side effects between the time periods of < 6 months, 712 months, 1324 months, and > 25 
months and still found no differences.  
 
Women respondents reported significantly higher mean scores for side effects than men (13.57 versus 
7.27; p < 0.001). Respondents receiving free ARVs reported significantly higher mean scores compared 
to those paying out-of-pocket for ARVs (18.03 versus 6.02; p < 0.01).  
 
An association was found between side effect scores and disease stage (as defined by CD4 counts). The 
highest mean scores were reported by patients who started ART with CD4 counts >201 cells/mm³; lower 
side effects scores were reported by patients starting ART at CD4 cell counts between 101-200 cells/mm³ 
and below 100 cells/mm3 (12.66 versus 8.10 versus 6.47; p< .01).  
 
 
Associations between adherence and sociodemographic chacteristics, and HIV disease- and 
ART-related variables  
 
The effect of a number of factors thought to be associated with ARV adherence was explored through 
bivariate analysis (Table 4). The study found that respondents with a university education were more 
likely to report higher adherence (mean 4-day adherence of ≥ 90 percent); respondents with less than five 
years of education were more likely to report lower adherence levels (mean 4-day adherence of < 90 
percent).  
 
Unemployed respondents were more likely to report lower adherence compared to those who were 
employed. Respondents receiving free ART through insurance-based programs were also more likely to 
report lower adherence compared to those who paid out-of-pocket. Interestingly, economic status was not 
found to be associated with adherence. 
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The time since diagnosis of HIV was not associated with adherence. The study also found no significant 
differences between respondents adherence levels and the duration of time on ART. Researchers were 
concerned that adherence levels would decrease among patients who had been on ART for longer periods 
of time.  
 
Patients who initiated ART when they had advanced HIV disease (defined as CD4 cell counts  
< 100 cells/mm3) were more likely to report higher adherence compared to respondents who initiated 
ART at higher CD4 cell counts. 
 
The study found that patients who reported being hospitalized two or more times in the past 12 months 
were more likely to report lower adherence compared to those who had been hospitalized once or not at 
all. 
 
Depression levels were found to be associated with adherence. Patients who reported moderate to severe 
depression were more likely to report lower adherence compared to respondents with minimal or mild 
depression.  
 
Taking fixed-dose combinations (FDC) in which all three ARV medications are combined into a single 
pill has been thought to enhance patient adherence to the treatment regimen. In India first-line treatment 
regimens are freely available and are the cheapest in the market (e.g., Triommune: D4T, 3TC, NVP; 
Duovir-N: AZT, 3TC, NVP). The majority of the study patients (84.5 percent) were taking a FDC with 
three first-line medications in one preparation. Taking FDCs, however, was not associated with higher 
adherence.  
 
As almost all patients (98 percent) were on a non-protease-inhibitor-containing treatment regimen, this 
variable was not analyzed further.  
 
The study collected self-reported data on the number of medications (both ARVs and non-ARVs) 
respondents were taking. Patients who were taking more than 7 pills/day were more likely to report lower 
adherence when compared to patients taking between 2 to 6 pills /day or < 2 pills /day, but the differences 
were not statistically significant (13 percent versus 16 percent versus 24 percent; p = 0.40). Respondents 
who had moderate to severe side effects were significantly more likely to report lower adherence than 
those who reported no or mild side effects.  
 
Overall, 54 percent of the respondents knew the names of the medications that they were taking. For those 
individuals who were unable to identify their medications, their physicians offices provided confirmation 
of the drug regimen or information was ascertained from the medicine packaging. Those who knew the 
names of their medications were more likely to report higher adherence than those who did not know 
what they were taking (59 percent versus 44 percent, p = 0.051). 
 
The study also explored the associations between alcohol use, drug use, and ART adherence. Lower 
adherence was found among those who had consumed alcohol in the past 30 days but the association was 
not significant. Eleven respondents reported ever using drugs and six respondents reported active drug use 
(in the past six months). Three of the six individuals reporting active drug use also reported lower 
adherence. Because of the small numbers further analysis was not conducted with this variable. 
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Table 4  Association of sociodemographic, HIV disease-, and ART-related variables with 
 adherence (bivariate analysis) 
 Higher adherence 
(> 90%) 
(n = 261) 
Lower adherence 
(< 90%) 
(n = 49) 
Significance* 
SOCIODEMOGRAPHIC VARIABLES    
    Age group    
        Less than 30 years (n = 51) 71 29 0.011 
        31 to 45 years (n = 204) 88 12  
        More than 45 years (n = 55) 84 16  
    Education    
        Less than 5 years of school (n = 30) 73 27 0.008 
        6 to 12 years of school (n = 165) 81 19  
        University (n = 115) 92   8  
    Employment    
        Employed (n = 255) 87 13 0.010 
        Unemployed (n = 55) 73 27  
    Economic status    
        Quartile 1 (n = 88) 81 19 0.558 
        Quartile 2 (n = 70) 83 17  
        Quartile 3 (n = 81) 85 15  
        Quartile 4 (n = 71) 89 11  
    Social support from family    
        Yes (n = 285) 85 15 0.529 
        No (n = 25) 80 20  
    Type of payment for ART    
        Paid out of pocket (n = 252) 89 11 0.000 
        Obtained free (n = 58)  60 40  
HIV DISEASE-RELATED VARIABLES    
    Time since HIV diagnosis    
        Less than 12 months (n = 55) 84 16 0.971 
        13 to 24 months (n = 73)  84 16  
        More than 24 months (n = 182) 85 15  
    Time since starting ART    
        Less than 12 months (n = 128) 82 18 0.512 
        13 to 24 months (n = 85) 84 16  
        More than 24 months (n = 97) 88 12  
    CD4 count at start of ART    
        Less than 100 cells/mm3 (n = 133) 89 11 0.001 
        101 to 200 cells/mm3 (n = 114) 86 14  
        More than 200 cells/mm3 (n = 59) 68 32  
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Table 4  Association of sociodemographic, HIV disease-, and ART-related variables with 
  adherence (bivariate analysis) (continued) 
 
    Number of hospitalizations due to 
    HIV-related illness 
   
        Never (n = 235) 85 15 0.011 
        Once (n = 58)  88 12  
        Two or more times (n = 17) 59 41  
    Depression    
        Minimal (n = 147) 93   7 0.000 
        Mild (n = 47) 83 17  
        Moderate (n = 54) 83 17  
        Severe (n = 61)  66 34  
ART-RELATED VARIABLES    
    Medication burden  
    (Number of all medications) 
   
        One medication (n = 117) 88 12 0.003 
        2–3 medications (n = 136) 87 13  
        4 or more medications (n = 56) 70 30  
    ART regimen    
        Fixed-dose combination (n = 262) 84 16 0.569 
        Non-FDC (n = 47) 89 11  
    Total pill burden    
        2 or fewer pills/d (n = 119) 87 13 0.409 
        3–6 pills/d (n = 166) 84 16  
        7 or more pills/d (n = 25) 76 24  
    Side effects    
        None to low scores (n = 278) 87 13 0.000 
        Moderate to high scores (n = 32) 56 44  
    Knowledge of medication    
        Knew medications (n = 166) 88 12 0.051 
        Did not know medications (n = 144) 80 20  
    Alcohol use    
        Yes (n = 47) 74 26 0.060 
        No (n = 255) 86 24  
    Ever drug use    
        Yes (n = 11) 55 45   0.018** 
        No (n = 299) 85 15  
   
*Chi Square Test  
**Fishers exact test  
Note: Percentages rounded to the nearest whole. 
 22 
Predictors of lower adherence 
 
To determine the independent predictors of lower adherence (mean 4-day adherence of < 90 percent), 
multivariate analysis using logistic regression was performed. Variables found to be significantly 
associated with adherence outcomes in the bivariate analysis were included.  
 
The following variables were found to be significantly associated with lower adherence on bivariate 
analysis and were included in the multivariate analysis: education, employment status, CD4 counts, 
number of hospitalizations, medication burden, source of funding for ARV medications, depression, and 
side effects.  
 
Based on the multivariate analysis, severe depression and obtaining free ARVs were found to be 
significantly associated with lower adherence. Patients with severe depression were four and a half times 
more likely to report lower adherence compared to those with minimal depression (OR 4.5; 95% CI = 
1.63912.269, p = 0.003). Patients receiving free ARVs were four times more likely to report lower 
adherence compared to patients paying out-of-pocket for their treatment (OR 4.0; 95% CI = 1.422
11.542, p = .009). 
 
 
Method of payment for ART  
 
The method of payment for ART as an independent predictor of lower adherence was further analyzed. 
As Table 5 shows, the mean four-day adherence was significantly lower among patients receiving free 
ART through an insurance program compared to those paying out-of-pocket for treatment. Adherence 
was significantly lower among patients receiving free ARVs on all self-reported measures of adherence.  
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Table 5  Self-reported adherence by method of payment 
 Out-of-pocket ART 
n = 252 
% 
Free ART 
n = 58 
% 
Significance
Mean 4-day adherence 96 81 0 .001* 
Missed one or more doses over last 4 days 11 40  0 .000** 
Missed doses over last week (7 days)    
    No doses missed 86 57  0 .000** 
    1 to 2 doses missed 11 19  
    3 or more doses missed   4 24  
Last time missed a full day’s medication    
    Never 72 41 0.000** 
    In the last 4 weeks   9 31  
    Between 1 to 3 months ago   9 10  
    More than 3 months back 10 17  
Number of times treatment stopped for more 
than 1 week 
   
    Never 88 66 0.000** 
    Once   8 21  
    2 or more times   4 14  
How closely did respondent follow ARV 
medication schedule 
   
    Always 81 40 0.000** 
    Most of the time 14 17  
    Some of the time   3 12  
    Never   3 31  
 
Note: Percentages may not add up to 100% since percentages were rounded to the nearest whole 
*T-Test and Mann Whitney U  
**Chi Square Test 
 
 
As Figure 2 shows, the mean four-day self-reported adherence was significantly lower among patients 
receiving free ART across the first three quartiles of economic status. Statistical analysis was not done for 
the highest economic status quartile because very few patients in this group accessed free ARVs (see 
Table 1, page 12). 
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Figure 2  Mean 4-day adherence by economic status quartiles 
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*T test and Mann Whitney U, p < .01 
 
 
The researchers examined adherence levels with regard to type of payment for ART and economic status. 
Using logistic regression analysis to control for economic status, the type of payment (out-of-pocket vs. 
insurance coverage) was found to be significantly associated with adherence. Patients receiving free ART 
through an insurance-based program were five times more likely to report lower adherence (mean 4-day 
adherence of < 90 percent) compared to those paying for ART. There was no association between 
economic status and adherence. 
 
 
Economic Aspects of Treatment 
 
Economic factors, including the cost of treatment and financing mechanisms to pay for treatment, can 
influence adherence and are important in India, given that between 75 and 85 percent of health care is 
delivered in the private sector. In this study, the majority of respondents (n = 252) accessed care in the 
private sector where they paid entirely out-of- pocket for antiretroviral medications and laboratory tests 
each time they accessed services. Forty-seven respondents received care from the public sector through 
employer-supported health insurance programs; no money was paid at the time of accessing services, 
including for medications and laboratory monitoring. A few respondents (n = 11) had employer-supported 
insurance coverage that allowed them to access care in the private sector where they paid money at the 
time of obtaining services and received reimbursement for all expenditures upon submission of bills.  
 
The researchers explored the financial aspects of treatment among all participants by asking about the 
amount spent on ART, sources of financing for treatment, and the potential impact of the long-term costs 
of ART on the household and on treatment adherence.   
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Costs of treatment 
 
The average monthly amount spent out of pocket on treatment (ARVs and diagnostics) was Rs 3,570 for 
all respondents in the sample (n = 310). For those who had no insurance coverage (n = 252) this amount 
was higher (Rs 4,376). A large proportion of respondents (43 percent) reported spending on average 
between Rs 500 to 2,000 per month and a quarter reported spending between Rs 2,000 to 3,000 per month 
(Table 6).  
 
 
Table 6  Percent distribution of monthly costs  (n = 310) 
Amount of money (Indian Rupees) Percent 
Rs 0 to 500  19 
Rs 501 to 2,000 43 
Rs 2001 to 3,000 24 
Rs 3001 to 4,000   4 
> Rs 4,001 10 
 
Note: Rs 43 = US$1 
 
 
Monthly expenditure on drugs for the entire sample was on an average Rs 1,775. For those without 
insurance coverage who were paying out-of-pocket the average monthly cost was Rs 2,159. Expenditure 
on diagnostic tests was as important as expenditure on ARV medications. The average monthly 
expenditure on laboratory diagnostics (routine monitoring tests, and HIV specific monitoring tests, such 
as CD4 counts and viral load) for all respondents was Rs 1,815 and was Rs 2,217 for those without 
insurance coverage. These figures indicate a major financial burden for those paying out-of-pocket for 
drugs and tests, especially for those patients who have no insurance coverage at all. 
 
Respondents were asked about expenditures incurred prior to initiating ART. Eighty-six percent of 
respondents reported they had to pay out-of-pocket for laboratory tests and other diagnostics before 
initiating ART. Respondents without insurance coverage reported an average expenditure of Rs 5,544 
compared to Rs 1,339 reported by respondents with insurance coverage. Paying for initial diagnostics can 
be a large financial burden (Gupta and Sankar 2000) even for persons able to access free ART.  
 
Study participants were asked about expenditures incurred for various laboratory tests in the past month. 
As shown in Table 7, 25 percent and 98 percent of respondents underwent viral loads and CD4 tests, 
respectively. The high cost of the viral load test may explain why fewer patients had this test. Given the 
high proportion of respondents who reported having had a CD4 count in the past month and the relatively 
large proportion whose costs were not fully covered, this monitoring test constitutes a large burden of the 
laboratory monitoring costs.  
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Table 7  Average out of pocket expenses for diagnostics and ARVs in the past month 
Diagnostics % reporting tests 
(n = 310) 
 
% whose costs  
were not fully 
covered* 
Average out-of-
pocket costs, if not 
fully covered (Rs) 
1. Routine laboratory tests 18 60    902 
2. CD4 test 98 84 1,839 
3. Viral load 25 86 4,741 
4. X-ray, radiological investigations   9 47 1,193 
5. All diagnostic tests    2,217 
6. ARV medications   2,159 
7. Total cost of treatment (5+6)   4,376 
 
*Of those who reported having had the test 
 
 
On average, respondents paid Rs 2,217 out-of-pocket for all diagnostic tests in the last month. The 
average monthly out-of-pocket cost of being on ART was Rs 4,376, which was equally divided between 
the cost of medications and the cost of laboratory monitoring. The combined cost of laboratory 
diagnostics and medication can place a significant economic burden on individuals and the household.  
 
 
Source of financing for treatment 
 
Respondents were asked about the source of financing for their treatment; multiple responses were 
permitted. A substantial proportion of respondents reported using their savings (43 percent) or their 
current earnings (37 percent) to finance their treatment (Table 8). A third of respondents reported 
receiving support from the family. Ten percent of respondents reported borrowing, which has the 
potential of burdening households and individuals with debt. 
 
 
Table 8  Source of financing for ARV medications (n = 310) 
Source Percent 
Savings 43 
Salary  37 
Family 33 
Insurance (ESIC/NRH/CGHS) 18 
Borrowing 10 
Sale of assets   3 
Other (e.g., personal insurance, NGO)   4 
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Economic burden of ART  
 
Study participants were asked how the economic burden of ART would impact their lives in the future; 
multiple responses were permitted. As shown in Table 9, more than half reported that it would deplete 
their personal savings and nearly a third reported that they would have to increase their borrowing. Nearly 
half the respondents said that continued expenditure on ART would impact the amount they could spend 
on housing and utilities, a quarter said it would reduce the amount they could spend on food, and a fifth 
reported that it would negatively impact their childrens schooling.  
 
 
Table 9  Effect of economic burden of ART on other aspects of life (n = 310) 
 Percent 
Depletion of savings 59 
Less money for utilities and housing 45 
Increased borrowing 31 
Less money available to provide financial support to other family members 30 
Less money for food 25 
Less money for children’s schooling 20 
Sale of assets 15 
 
 
Life-long commitment to ARVs 
 
Respondents were asked about their commitment to taking ARVs for the rest of their lives. Sixty-four 
percent of respondents said that they would be able to continue taking ARVs for the long-term. The most 
frequently cited reasons were to live longer, to care and provide for their families, and to be well in order 
to pay for the medications. Around a third of respondents were unsure of their ability to continue due to 
the uncertainty of their employment and financial situations. Less than four percent said that they didnt 
think they would be able to continue taking the medications in the long term mainly because of financial 
constraints. 
 
I have to increase my life span to complete those incomplete tasks. Every one will die one day. 
What will other people say if I die before my parents. I have to look after my brother’s children too.  
35-year-old male client accessing services in the private sector 
 
I get interest from the money I saved and I can spend it so I feel I will always be able to take the 
medicine.  
35-year-old male client accessing services in the private sector 
 
[I’m not sure I will be able to], I have no income source; I am totally dependent on others.  
33-year-old male client accessing care in the private sector 
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[I am not sure] they give medicines for so long… will get tired of taking them [for so long] 
25- year-old female client accessing services in the public sector and covered by insurance 
 
Patients paying out-of-pocket for ART at Ruby Hall Clinic were asked whether they would move to a 
government facility when free ARVs became available through the national program. Seventy-one 
percent of respondents said that they would move primarily for financial reasons. Ten percent of 
respondents were unsure if they would move to a government facility. Around 19 percent said that they 
would not move to a government facility to receive free ARVs. The main reasons these respondents (n = 
70) indicated that they wouldnt switch to the public sector were concerns about confidentiality (34 
percent), fear of poor quality of care and medications (30 percent), and trust in their current physician (7 
percent). 
 
Yes [I will move] I can save that much money and use it for my children’s future. 
35-year-old male 
 
Yes [I will move], if the medicines of that company are standard, then I will take. Otherwise no.  
34-year-old male 
 
No [I will not move] I do not trust the quality of medicines.  
55-year-old male 
 
No [I will not move] they will not follow secrecy.  
40-year-old male 
 
 
Sexual Behavior 
 
This study explored the sexual behavior of respondents and their relationships with regular partners and 
casual partners within the last six months. Male respondents were also asked about sexual activity with 
sex workers and male sex partners. Although they were receiving ART, four respondents (three women 
and one man) were not included in the analysis on sexual behavior because they were not aware of their 
HIV status. These respondents reported that their respective families were told of their illness.  
 
Key themes of analysis were type of partners, knowledge of partner status, disclosure of own HIV status 
to partners, condom use at last sex, and consistent condom use. 
 
 
Reported sexual activity in the past six months 
 
As per national guidelines ART is initiated by HIV-positive patients with CD4 cell counts of less than 
200 cells/mm3 or when they are in Stage IV of HIV disease (WHO classification for disease staging). At 
this point, patients can be quite sick and many will have experienced one or more episodes of 
opportunistic infections. Once patients begin ART their immune systems and health status improve, and 
many are able to engage in sexual activity. Researchers explored the factors influencing sexual activity 
among respondents.  
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As Table 10 shows, 61 percent of respondents reported having had sex during the reference period.  
Not surprisingly, marital status was strongly associated with reporting sex; married respondents reported 
sexual activity more often than single or separated/divorced/widowed respondents.  
 
Disease stage at the start of ART, based on CD4 counts, was found to be associated with reported sexual 
activity. Patients who had initiated ART with advanced HIV disease (CD4 cell counts < 100 cells/mm 3) 
were significantly less likely to report sexual activity in the past six months compared to respondents who 
had initiated ART with higher CD4 cell counts (p = 0.037). Study participants with moderate to severe 
depression were less likely to report sexual activity in the past six months compared to those with 
minimal depression.  
 
Age, time since HIV diagnosis, and duration on ART were not associated with respondents sexual 
activity during the reference period.  
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Table 10  Self-reported sexual activity in the past 6 months  
 % reporting sex  
 in past 6 months 
(n = 187) 
Significance* 
Sex   
    Male (n = 260) 61 .771 
    Female (n = 46) 63  
Age   
    Less than 30 years (n = 49) 63 .646 
    31 to 45 years (n = 203) 62  
    More than 46 years (n = 54) 56  
Marital status   
    Currently married (n = 260) 69 .000 
    Single (never married) (n = 21) 33  
    Separated/divorced/widowed (n = 25) 8  
Time since HIV diagnosis   
    Less than 12 months (n = 55) 62 .436 
    13 to 24 months (n = 73) 67  
    More than 24 months (n = 178) 58  
Time since starting ART   
    Less than 12 months (n = 125) 62 .578 
    13 to 24 months (n = 85) 57  
    More than 24 months (n = 96) 64  
CD4 count at start of ART   
    Less than 100 cells/mm3 (n = 133) 53 .037 
    101 to 200 cells/mm3 (n = 113) 66  
    More than 200 cells/mm3 (n = 56) 70  
Depression   
    Minimal (n = 147) 70 .015 
    Mild (n = 45) 62  
    Moderate (n = 54) 46  
    Severe (n = 59)  54  
 
Note: Percentages rounded off to nearest whole 
*Chi square test  
 
 
Type of partners 
 
Respondents who reported sexual activity in the past six months (n = 187) were asked about the different 
types of partners they had sex with during the reference period. A regular partner was defined as a spouse, 
someone with whom the respondent lived, or a stable, steady partner. A non-regular or casual partner was 
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defined as a partner the respondent was not living with, married to, and rarely had sex with. A sex worker 
was defined as a partner the respondent paid money or gave gifts to in exchange for sex. 
 
Ninety-six percent (180 of 187) of respondents who reported being sexually active in the past six months 
reported having sexual intercourse with a regular partner. Only four percent (8 of 187) of respondents 
reported having had sexual intercourse with a casual partner and two percent (3 of 187) with a sex 
worker. All the respondents who reported sex with a casual partner or a sex worker were male. 
 
Male respondents were also asked whether they had sex with a male partner. Three of the 158 sexually 
active male respondents reported ever having sex with a male partner; none reported sex with a male 
partner during the reference period.  
 
 
Regular partner relationships 
 
Because the majority of respondents reported sexual activity with a regular partner, these relationships 
were explored in greater detail. 
 
Knowledge of HIV status of regular partners: Partner status reported here is based on patient report; HIV 
testing was not conducted. Respondents were asked whether or not they knew the HIV status of their 
regular partner. Overall 83 percent of respondents who reported sex with a regular partner reported 
knowing their partners HIV status. Forty-three percent reported an HIV-positive partner, 40 percent an 
HIV-negative partner, and 17 percent reported not knowing their partners HIV status.  
 
Statistically significant differences were seen between men and women (p < .001). As Figure 3 shows, 
more men reported an HIV-negative partner than women (45 percent  versus 11 percent) and more men 
reported not knowing their partners HIV status compared to women (18 percent  versus 14 percent). 
More women reported having an HIV-positive regular partner (75 percent  versus 38 percent). These 
findings reflect current trends in India of Indian women being predominantly infected by their 
spouses/regular partners (NACO 2002). 
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Figure 3  Gender differences in reported knowledge of regular partner's HIV status  
 (n = 180) 
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As Table 11 shows, fewer respondents with less than five years of school education were likely to report 
knowing their regular partners status than those with more than six years of education or university 
education. However, the difference was not statistically significant. Time since diagnosis of HIV and time 
on treatment with antiretroviral therapy were also not associated with knowledge of partners HIV status.  
 
 
Table 11  Knowledge of regular partner’s HIV status (n = 180) 
   % know Significance* 
Education   
    Less than 5 years of school (n = 23) 69 .365 
    6 to 12 years of school (n = 88) 86  
    University (n = 69) 87  
Time since HIV diagnosis   
    Less than 12 months (n = 34) 79 .374 
    13 to 24 months (n = 47) 79  
    More than 24 months (n = 99) 86  
Time since starting ART   
    Less than 12 months (n = 77) 81 .344 
    13 to 24 months (n = 44) 82  
    More than 24 months (n = 59) 86  
  
Note: Percentages rounded off to nearest whole 
*Chi Square Test  
 
 
Disclosure of own HIV status to regular partner: Overall, 74 percent of respondents reported having 
disclosed their HIV status to their regular partner, and 98 percent of these individuals were married. 
Among married respondents 25 percent reported not having disclosed their HIV status to their spouse. 
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As Table 12 shows, fewer men reported having disclosed their HIV status to their regular partner 
compared to women (73 percent versus 82 percent), but the difference was not statistically significant.  
 
Education, time since diagnosis of HIV disease (time since testing positive), and time on ART were not 
found to be significantly associated with disclosure of HIV status to regular partners.  
 
Respondents with advanced HIV disease (defined as CD4 cell counts < 100cells/mm3 at start of ART) 
reported significantly lower disclosure rates when compared to respondents with less advanced disease 
stages (CD4 cell counts between 100200 cells/mm3 at start of ART and respondents with CD4 cell 
counts > 200 cells/mm3 at start of ART).  
 
Disclosure was significantly associated with a regular partners HIV status. Respondents with a HIV-
positive partner were significantly more likely to report disclosure of their HIV status compared to 
respondents with an HIV-negative partner or respondents with a partner of unknown HIV status. The 
lowest disclosure rates were observed with partners of unknown HIV status. 
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Table 12  Disclosure of own HIV status to regular partners and reported condom use with 
  partner at last sex (n = 179) 
 Disclosure Condom use 
 % disclosed Significance % used Significance 
Gender     
    Male (n = 133) 73 .301 90 .206* 
    Female (n = 46) 82  82  
Education     
    Less than 5 years of school  
    (n = 23) 
70 .824 65 .001 
    6 to 12 years of school (n = 87) 76  92  
    University (n = 69) 74  93  
Time since HIV diagnosis     
    Less than 12 months (n = 33) 70 .072 79 .134 
    13 to 24 months (n = 47) 63  89  
    More than 24 months (n = 80) 81  92  
Time since starting ART     
    Less than 12 months (n = 76) 71 .317 86 .436 
    13 to 24 months (n = 44) 71  93  
    More than 24 months (n = 59) 81  90  
CD4 count at start of ART     
    Less than 100 cells/ mm3 (n = 70) 64 .040 89 .415 
    101 to 200 cells/mm3 (n = 71) 83  92  
    More than 200 cells/mm3 (n = 35) 74  83  
Partner HIV status     
    HIV-positive (n = 78) 83 .003 83 .051 
    HIV-negative (n = 70) 74  96  
    Don’t know (n = 31) 52  87  
Depression     
    Minimal to mild (n = 125) 70 .069 94 .002 
    Moderate to severe (n = 55) 83  78  
        
Note: Chi Square Test unless otherwise noted 
*Fishers Exact Test 
 
 
Condom use with a regular partner: Eighty-nine percent of respondents used a condom the last time they 
had sexual intercourse with their regular partner. Ninety-eight percent of respondents who reported 
having had sex with a regular partner during the reference period were married. Of these, 89 percent 
reported using a condom with their spouse the last time they had sex. 
 
As shown in Table 13, a higher proportion of male respondents reported condom use during their last 
sexual experience with a regular partner compared to female respondents (90 percent versus 82 percent), 
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but the difference was not statistically significant. Condom use was not found to be associated with time 
since diagnosis of HIV (testing positive for HIV), disease stage (defined by CD4 cell counts at start of 
ART), or time on ART. 
 
Respondents with less than five years of education reported significantly lower condom use compared to 
those with higher levels of education. 
 
Condom use was more common with an HIV-negative partner. Ninety-six percent of respondents with an 
HIV-negative partner reported using a condom at last intercourse compared to 83 percent with a HIV-
positive partner and 87 percent with a partner of unknown HIV status.  
 
Patients with moderate to severe depression reported lower condom use compared to those with minimal 
to mild depression, and the difference was statistically significant. 
 
Consistent condom use (always used a condom) with a regular partner was reported by 80 percent of 
respondents (data not shown). 
 
Patients who reported not using a condom at last intercourse with their regular partner (n = 20) were 
asked why. Having an HIV-positive partner was the most frequently cited reason, followed by dislike of 
condoms and lack of awareness of the importance of condom use by HIV-positive persons (Table 11). 
 
 
Table 13  Reasons for not using a condom at last sex with a regular partner (n = 20) 
Reason Number of times mentioned 
Partner is HIV-positive 6 
Don’t like using condoms 3 
Did not know about using condoms for this disease 3 
Did not feel the need to use condoms 2 
Found it difficult to discuss condoms 2 
Did not have condoms at hand 2 
Never used condoms 1 
Not disclosed status to partner 1 
Condoms take away romance from sex 1 
Would make partner suspicious 1 
Condoms are difficult to use 1 
      
Note: Respondents could report more than one reason 
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Relationships with casual partners, sex workers, and male partners 
 
Eight (all males) of the 187 respondents who reported being sexually active in the past six months 
reported sex with a casual partner. Two respondents had been on ART for less than 12 months, two were 
on ART for 12 to 24 months, and four had been on ART for more than 24 months. 
 
Three males reported having sex with a sex worker. One respondent had been on ART for more than 12 
months and two had been on ART for more than 24 months. 
 
Five of eight respondents who reported having sex with a casual partner did not know their partners HIV 
status and the other three thought their partner was HIV-negative. Only one respondent reported actually 
asking his casual partner about her HIV status. The three respondents who reported sex with a sex worker 
did not know her HIV status. None reported asking about the sex workers HIV status. 
 
All eight respondents who reported having sex with a casual partner and the three respondents who 
reported having sex with a sex worker reported not disclosing their own HIV status to these partners. 
However, all 11 reported using a condom the last time they had sexual intercourse with them. 
 
Whereas two percent (4 out of 260) of male respondents reported ever having sex with a male partner, 
none reported having sex with a male partner during the reference period.  
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Discussion 
 
 
The study was designed to be an exploratory study on adherence and included HIV-infected individuals 
accessing services in both private and public sector health facilities. As the free national ART program 
had not yet started, patients from public sector sites were recruited from employer-provided, insurance-
based health programs. Although a majority of the patients were employed in either the public or private 
sectors, they were not representative of all HIV-infected individuals accessing ART in India at the time of 
the study. However, study findings provide important insights into adherence, sexual behavior, and the 
economic burden of treatment that are relevant to the national ART program as it scales up. 
 
The study results show high levels of adherence in a large proportion of HIV-infected adults receiving 
ART at one private and three public sector facilities in a developing country and resource-limited setting. 
This study also found that patients who had insurance coverage resulting in the availability of free ARVs 
had lower adherence on all measures of adherence, which demonstrates an association between insurance 
coverage and adherence. These differences in adherence levels were seen even after controlling for 
economic status. It is important to emphasize that this study is not a comparison between private and 
public sector health facilities, but rather a comparison between HIV-infected individuals who pay a 
significant amount of out-of-pocket costs and those who pay a small proportion of their salary into an 
employer-provided insurance program to receive free ART. Possible explanations for the differences 
between the two groups include:  
 
• Neither the private nor public sector facilities had formal adherence support programs or adherence 
counseling services in place, although doctors at all facilities provided adherence-related information to 
their patients. However, patients in the private sector were assessed for their ability to afford treatment 
and their readiness to start therapy prior to initiating ART. Thus, this difference in patient preparation 
prior to initiating ART may have contributed to the differences in adherence measures between the two 
groups.  
 
• The disease stage at which ART was initiated may have had an influence on adherence levels. The 
majority of patients who paid out-of-pocket for their treatment initiated ART with very advanced HIV 
disease and so may have experienced serious and/or life-threatening opportunistic infections. As free 
ARVs were available, doctors in the public sector may have initiated treatment based on clinical staging 
and less stringent CD4 cell criteria, as is evident from the proportion of patients in the public sector 
with higher baseline CD4 counts when compared to patients in the private sector. These patients may 
not have experienced severe opportunistic infections with higher CD4 cell counts, and as a result, this 
may have influenced their perceptions about disease severity and the need to maintain high levels of 
adherence. 
 
• Patients in the private sector were paying significantly higher amounts out-of-pocket for medications 
and laboratory tests than patients in the insurance programs who paid relatively insignificant amounts 
when accessing services. These differences may have influenced how each group valued its treatment, 
thereby contributing to differences in adherence.  
 
• Patients in insurance-based programs usually procured medications from selected public sector 
dispensaries, which in turn needed to request medications from central suppliers. This requires advance 
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planning to prevent stock-outs. Purchasing medications from chemists shops often ensures better 
availability. Stock-outs and breaks in availability of ARVs in public sector dispensaries and patients 
financial difficulties may have contributed to lower adherence among this group. Running out of pills, 
including stock-outs, was the third most common reason cited by respondents for missing doses over 
the past week. 
 
Severe depression was found to be an independent predictor of lower adherence in this study. In their 
review paper, Ichovics and Meade (2002) noted that a similar finding had been reported in other studies. 
Providers need to be alert to the presence of depression among their patients. Early identification and 
management of severe depression and interventions to provide adherence support may be required to 
maintain high levels of adherence. 
 
On univariate analysis, the study found that lower education, starting ART at higher baseline CD4 cell 
counts, being unemployed, having moderate to severe side effects, and taking four or more medications 
(in addition to severe depression and receiving free ARV medications) were factors associated with lower 
adherence. Although these factors were not independent predictors of adherence on multivariate analysis, 
it is important that providers keep them in mind when deciding if certain patients need stronger adherence 
counseling and support.  
 
There was widespread concern that patients on ART would become less adherent once they began to feel 
better physically. This study did not find any evidence supporting this view. There was no significant 
difference in the mean self-reported 4-day adherence between patients who had been on ART for less than 
12 months, 13 to 24 months, or more than 24 months. 
 
The study found that patients accessing ART services in the private sector were almost equally distributed 
across the four economic status quartiles based on ownership of assets. Patients from employer-supported 
insurance programs were distributed mostly across the first three economic status quartiles. In India 
almost 80 percent of health care is provided by the private sector, and people from lower economic strata 
also access services in the private sector. This study shows that poorer people also access the private 
sector for ART services, despite the great expense. Additionally, the study found that economic status was 
not related to adherence, a finding similar to the results of other studies (Ichovics and Meade 2002). 
However, 71 percent of the patients accessing services at RHC reported that they would move to the 
national ART program once it started, mostly for financial reasons. It would be interesting to see whether 
adherence levels change among clients who move from the private sector to public sector health facilities 
for ART. 
 
Other research findings have identified side effects as an important factor that influences adherence 
(Ichovics and Meade 2002). This study found that the majority of respondents had low side effect scores, 
indicating that side effects were present but not particularly bothersome. There were no differences in side 
effect scores for different durations on ART. Higher side effect scores were reported by women and 
respondents who started treatment with higher baseline CD4 counts. This suggests that patients who are 
very sick and for whom ART is a life-saving treatment may tolerate side effects better than others. With 
regard to women this may be an indication of a difference in the severity of side effects or lower levels of 
tolerance.  
  
The majority of respondents were married and most of the reported sexual activity in this study was with 
a regular partner. More than a third of respondents (39 percent) were in a discordant relationship with an 
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HIV-negative partner and this was disproportionately higher for male respondents. A quarter of married 
respondents had not disclosed their HIV status to their partners. Disclosure was lower to a HIV-negative 
partner and lowest to a partner of unknown HIV status, which highlights the need for prevention 
counseling programs to emphasize and facilitate disclosure of HIV status to partners.  
 
Overall reported condom use with a regular partner was high. Although 96 percent of respondents with an 
HIV-negative regular partner reported using a condom at last sexual contact, condom use with a partner 
of unknown status was lower (87 percent). Lower disclosure to partners of unknown status coupled with 
lower condom use sets the stage for the risk of transmission of infection to these partners.  
 
The percentage who reported consistent condom use with a regular partner was less than the percentage 
who reported condom use at last sexual contact; a fifth did not use condoms consistently. Inconsistent 
condom use coupled with a high proportion of discordant couple relationships and couples with partners 
of unknown status is a matter of concern. Inconsistent condom use is also a concern for sero-concordant 
partners because of the risk of re-infection with new viral strains, which in turn accelerate disease 
progression. Not using condoms also carries the risk of unwanted pregnancy and the subsequent 
transmission of HIV to the child. 
 
It was encouraging to observe that even though the majority of respondents who reported sex with a 
casual partner or sex worker did not know their partners HIV status nor disclose their own status, all 
reported using a condom at last sexual contact with these partners. We are, however, unable to rule out 
the extent to which social desirability may have influenced these and other sexual behavior responses.  
Although the study found some evidence of risk behaviors among respondents on ART (e.g., unprotected 
sex, sex with casual partners and sex workers), overall there were relatively low levels of reported risky 
behavior. Low-risk behavior may be explained when taking into account many study participants 
historygetting tested and diagnosed, having HIV disease advanced enough to warrant treatment, and 
having had several contacts with health workers (treating physicians, nurses, counselors, etc.) who 
conveyed prevention and protection messages during the course of treatment. 
 
Although there is concern that risky sexual behavior may dramatically increase once HIV-positive 
persons feel better on treatment, this study did not support this view. There were no significant 
differences in sexual behavior, disclosure rates, and condom use by respondents on ART for different 
periods of time (less than 12 months, 13 to 24 months, and more than 24 months). 
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Program Implications and Recommendations 
 
 
This exploratory study was conducted among HIV-infected individuals accessing ART in two categories 
of health service facilities: the private sector and the insurance-based public sector. In April 2004, the 
national ART program opened a third sector: free ART at selected public sector facilities.  
 
Although overall adherence among study participants was high, the data indicate that adherence was 
lower among patients who received free ART through insurance-based programs. No information is 
available yet on adherence levels among patients who are receiving free ARVs through the national ART 
program to which the data from this study could be compared. Therefore, there is need for a larger multi-
site study with HIV-infected persons receiving free ART through the national ART program. 
Additionally, almost 80 percent of health care in India is provided in the private sector, which consists of 
a heterogeneous mix of providers ranging from small individual physician practices, to polyclinics, 
NGOs, charitable clinics, research institutes, private hospitals, nursing homes, etc. This research 
highlights the need for more studies with a range of private providers and facilities to better understand 
the dynamics of adherence in this sector. 
 
Lower adherence among patients receiving free ARVs through insurance-based, public sector facilities 
highlights the need for a strong monitoring and evaluation component in the national ART program as it 
scales up. The program may benefit from a strong focus on: 
• Adequate education of patients about ART issues (including adherence and side effects) prior to 
initiation. 
• Regular assessments of adherence levels during follow-up. 
• Provision of ongoing adherence support where needed, even as evidence on adherence and risk 
behavior in the program is being gathered. 
 
The small number of patients with insurance coverage who accessed services at NRH and ESIC raises the 
important question of why so few people chose to access free ARVs at these sites. This makes it 
imperative to carry out research into the potential barriers to treatment access at these sites, such as lack 
of awareness of the program among the target population, lack of awareness of the program among health 
providers, poor health provider training and attitudes, lack of VCT services, and stigma and 
discrimination issues, among others.  
  
This study included relatively few women. Although the respondents were not representative of the entire 
population accessing ART services in India, the low figure still calls attention to the need for 
policymakers to make sure that women are included in the national ART program. 
 
The study indicated that a significant proportion of patients would switch to the free ARV program if 
their concerns about the quality of ARV medications, confidentiality, and continuous supply of 
medications were met. This means that the national ART program needs to pay attention to quality of care 
while preparing for an influx of patients who currently access care services in the private sector.  
 
The study found that out-of-pocket expenses for treatment (ARV medications, treatment monitoring, and 
consultation fees) pose a significant economic burden on clients who pay for services. The study also 
found that out-of-pocket expenses influence adherence in a positive way. However, there is probably a 
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fine line between out-of-pocket expenses fostering adherence and free ARVs resulting in suboptimal 
adherence. This has significant implications for the design of a treatment program, and the optimal 
pricing of it to elicit maximum adherence. It is clear that these study results need to be further 
investigated; therefore, policymakers should consider further operations research to determine optimal 
levels of user fees to maximize adherence.  
 
During adherence risk assessment of patients before the initiation of ART, health providers should focus 
on depression as a key predictor of lower adherence. Health providers may also need to focus on other 
factors that may influence adherence to a lesser degree: lower education levels, starting ART at higher 
baseline CD4 cell counts, being unemployed, having moderate to severe side effects, and taking four or 
more medications.  
 
Traditionally prevention programs in India have focused on high-risk groups such as sex workers, men 
who have sex with men, truckers, etc. The evidence from this study highlights the need for expanding the 
scope of prevention programs to include HIV-positive populations, with a special emphasis on facilitating 
disclosure and consistent condom use within regular partner relationships. Although sero-discordant 
couples remain the focus of prevention efforts, sero-concordant couples also need to be kept in mind 
because the risk of reinfection with a different strain of HIV remains. Prevention-related interventions 
that integrate HIV prevention activities with HIV/AIDS care services are required.  
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